Although Lilly’s balance sheet benefits from record sales, its heavy reliance on a single drug class introduces a risk that is often overshadowed by enthusiasm for the GLP-1 segment. Should competitive dynamics shift or regulatory developments emerge that curb prescription growth, Lilly would face a significant revenue challenge. For now, however, equity markets continue to price the company for near-perfect execution.
Merck’s Therapeutic Focus and Pipeline
Merck, which does not compete in the GLP-1 space, concentrates on oncology, infectious diseases and cardiometabolic conditions. The company’s leading product, Keytruda, is among the most widely prescribed immuno-oncology agents worldwide. U.S. patent exclusivity for Keytruda expires later this decade, raising concern about potential revenue erosion. Nonetheless, Merck’s management points to several mitigating factors.
International patent protections for Keytruda extend into the early 2030s, allowing the drug to remain a meaningful contributor in many markets even after U.S. exclusivity lapses. In addition, Merck is pursuing a new delivery formulation that could lengthen overall patent life into the late 2030s. The company also reports a broad pipeline of experimental therapies at various stages of development targeting cancer, infectious pathogens and metabolic disorders.
Analysts believe these assets, combined with strategic licensing agreements, may help offset the eventual decline in Keytruda’s U.S. revenue. According to the U.S. Food and Drug Administration, the company currently has multiple investigational new drug applications under review, reflecting ongoing research activity.
Valuation Gap Favors Merck
From a valuation perspective, Merck trades at roughly 16 times earnings, a level viewed as more in line with historical pharmaceutical norms. The company’s dividend yield is approximately 2.8 percent—more than four times Lilly’s rate. Merck has increased its dividend gradually for over 30 years, albeit not on a strictly annual schedule. Its payout ratio is about 50 percent of earnings, suggesting sufficient coverage and leaving room for potential future increases barring a sharp earnings contraction.
The divergence in multiples underscores different investor expectations. Lilly’s elevated P/E reflects confidence that GLP-1 sales will continue expanding quickly and sustainably. Merck’s lower multiple implies more moderate growth prospects but also indicates a margin of safety for shareholders focused on income and valuation discipline.
Imagem: Internet
Risk Profiles Differ Markedly
Lilly’s growth trajectory is closely tethered to two medications. Any adverse event—whether competitive entries, supply constraints or shifting medical guidelines—could have an outsized impact on revenue. While the company maintains a broader pipeline, no other current product approaches the scale of Mounjaro or Zepbound.
Merck’s reliance on Keytruda is notable but partially mitigated by staggered international patent expirations and the company’s work on alternative delivery systems. Additionally, Merck’s disease-area diversification and active research portfolio provide multiple channels for revenue replacement.
Dividend Considerations
Investors pursuing stable income streams typically prioritize yield, payout sustainability and historical trends of dividend support. Merck checks each of these boxes with a yield near 3 percent and decades of upward adjustments supported by earnings. Lilly, by contrast, channels a larger share of cash toward research, development and capacity expansion for its GLP-1 franchise, leaving limited funds for dividend growth in the near term.
A 0.6 percent yield may not satisfy traditional dividend investors, although growth-oriented shareholders could still favor Lilly on the expectation that rapid earnings expansion will eventually translate into higher distributions or share repurchases. For now, however, the company’s policy prioritizes capital deployment to accelerate product supply and pipeline progress.
Strategic Takeaways for Investors
Both companies operate from positions of financial strength and maintain significant research programs. The key distinction lies in how the market currently values those prospects and how each firm rewards shareholders through dividends.
Merck offers investors a comparatively moderate earnings multiple and an above-average yield, supported by a long track record of incremental dividend growth. Lilly delivers exceptional revenue momentum rooted in GLP-1 leadership but trades at a premium valuation and provides minimal income. These contrasting profiles give investors clear alternatives depending on individual priorities regarding growth versus income and tolerance for product-specific risk.
While neither stock is inherently flawed, the choice between the two hinges on whether an investor favors the potential upside of an aggressively priced growth story or the steadier cash return of a more modestly valued pharmaceutical giant.
